uploads///Chart  NVS

Assessing the Performance of Novartis Stock in 1Q18


Apr. 9 2018, Updated 4:30 p.m. ET

A look at Novartis

Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company that specializes in researching, developing, manufacturing, and marketing a broad range of healthcare products.

The company reports its business in three segments: Innovative Medicines, Sandoz (its generics business), and Alcon (its eye care business).

The chart above compares Novartis’s revenues and EPS (earnings per share) since 1Q16 along with estimates for its 1Q18.

Article continues below advertisement

Stock price performance

Novartis stock has fallen ~7.0% in 1Q18, and it’s fallen 4.5% YTD (year-to-date) as of April 6, 2018.

Analysts’ recommendations

Wall Street analysts expect Novartis to return ~22.3% over the next 12 months. Analysts’ recommendations show a 12-month target price of $98.06 on the stock compared to its price of $80.20 on April 6, 2018.

There are four analysts tracking Novartis’s ADR (American depositary receipt). Of these, one analyst recommends a “strong buy,” one recommends a “buy,” one recommends a “hold,” and one recommends a “sell.”

Article continues below advertisement

There are 27 analysts tracking Novartis stock as it’s listed on the SIX Swiss Exchange. Of these, seven analysts recommend “strong buys,” nine recommend “buys,” eight recommend “holds,” and three recommend “sells.” The consensus rating for Novartis stands at 2.26, which represents a strong buy for value investors and a moderate buy for long-term investors.

Analysts’ revenue estimates

Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines business, while its Sandoz and Alcon businesses also contribute toward its overall growth.

Analysts expect Novartis to report revenue of $12.4 billion in 1Q18, a ~7.4% rise compared to 1Q17. They expect its EPS to be $1.29 in 1Q18.

The BLDRS Europe Select ADR ETF (ADRU) holds 21.0% of its total investments in healthcare companies. ADRU holds 6.1% in Novartis AG ADR (NVS), 2.8% in GlaxoSmithKline ADR (GSK), 2.6% in AstraZeneca ADR (AZN), and 2.7% in Sanofi ADR (SNY).


More From Market Realist

  • BioNano Genomics Saphyr system
    Company & Industry Overviews
    BioNano Genomics (BNGO) Stock Looks Like a Buy, Solid Opportunity
  • Delta aircraft
    Company & Industry Overviews
    Delta Air Lines Updates Mandatory Vaccine Policy, Explained
  • AMC advertisement in walkway
    Company & Industry Overviews
    Why It's Time for Most Investors to Sell AMC Entertainment Stock
  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.